医学
联会
PSL公司
面瘫
泼尼松龙
皮质类固醇
麻痹
面部对称
外科
儿科
几何学
数学
病理
替代医学
作者
Satoru Baba,Kenji Kondo,Ai Yoshitomi,Kenshiro Taniguchi,Muneo Nakaya,Tatsuya Yamasoba
出处
期刊:Otology & Neurotology
[Ovid Technologies (Wolters Kluwer)]
日期:2022-11-29
卷期号:44 (2): e103-e107
标识
DOI:10.1097/mao.0000000000003762
摘要
Objectives To evaluate the efficacy of high-dose corticosteroid for severe acute facial paralysis in children. Methods The present study enrolled 10 pediatric patients with House-Brackmann (H-B) Grade VI facial paralysis who received prednisolone (PSL) 3 to 4 mg/kg/d for 2 to 3 days followed by a 10-day taper (the child high-dose group). Eight pediatric patients who received PSL 0.5 to 1 mg/kg/d were enrolled in a child low-dose group, and nine adult patients (25–64 yr) who received a high-dose PSL 200 mg equivalent for 2 to 3 days followed by a 10-day taper were enrolled in an adult high-dose group. On the initial and follow-up visits, facial movements were evaluated using the H-B grading system. The degree of oral-ocular synkinesis was evaluated by the degree of asymmetry in eye-opening width during mouth movements. The synkinesis index was defined as a percentage of the interpalpebral space width ([normal side − affected side]/normal side). Results The child high-dose group achieved a significantly better H-B score than the child low-dose group ( p < 0.01). The synkinesis index was significantly lower in the child high-dose group than in the child low-dose group or the adult high-dose group ( p < 0.05). Conclusion Children receiving PSL 3 to 4 mg/kg/d achieved better recovery and less synkinesis than those treated with low-dose PSL (0.5–1 mg/kg/d).
科研通智能强力驱动
Strongly Powered by AbleSci AI